Gain Therapeutics Advances Parkinson’s Treatment with GT-02287 Study

Gain Therapeutics, Inc. ((GANX)) announced an update on their ongoing clinical study.

Gain Therapeutics, Inc. is conducting a clinical study titled An Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Participants With Parkinson’s Disease With or Without a Pathogenic GBA1 Mutation. The study aims to evaluate the safety and tolerability of GT-02287, a potential treatment for Parkinson’s Disease, by examining its absorption, distribution, and removal from the body, as well as its biological effects in blood and cerebrospinal fluid.

The intervention being tested is GT-02287, an experimental drug administered orally once daily for 90 days. The drug is designed to assess its safety and potential benefits in treating Parkinson’s Disease symptoms.

This Phase 1 study follows an interventional, single-group model without masking, focusing on treatment. All participants receive GT-02287, and the study’s primary purpose is to evaluate the treatment’s effects.

The study began on December 9, 2024, with the latest update submitted on May 5, 2025. These dates are crucial as they indicate the study’s progress and ongoing recruitment status.

The update on this study could influence Gain Therapeutics’ stock performance by boosting investor confidence in the company’s research capabilities. As the study progresses, positive outcomes could enhance market sentiment and position Gain Therapeutics favorably against competitors in the Parkinson’s treatment landscape.

The study is currently ongoing, with further details available on the ClinicalTrials portal.